KRTX Insider Trading Activity and SEC Form 4 Filings
KRTX insider trading summary
No open-market insider purchases or sales of Karuna Therapeutics, Inc. (KRTX) have been reported on SEC Form 4 in the past 12 months.
Latest KRTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 8, 2024 | Stephen K. Brannan | Chief Medical Officer | Sell | $32K (100 @ $318.96) |
| Mar 8, 2024 | Stephen K. Brannan | Chief Medical Officer | Sell | $1.6M (4,900 @ $318.33) |
| Feb 8, 2024 | Stephen K. Brannan | Chief Medical Officer | Sell | $259K (818 @ $316.56) |
| Feb 8, 2024 | Stephen K. Brannan | Chief Medical Officer | Sell | $1.3M (4,182 @ $316.05) |
| Jan 8, 2024 | Stephen K. Brannan | Chief Medical Officer | Sell | $4.8M (15,000 @ $316.81) |
| Dec 8, 2023 | Stephen K. Brannan | Chief Medical Officer | Sell | $313K (1,565 @ $200.11) |
| Dec 8, 2023 | Stephen K. Brannan | Chief Medical Officer | Sell | $459K (2,251 @ $203.80) |
| Dec 8, 2023 | Stephen K. Brannan | Chief Medical Officer | Sell | $805K (3,969 @ $202.74) |
| Dec 8, 2023 | Stephen K. Brannan | Chief Medical Officer | Sell | $20K (99 @ $204.18) |
| Dec 8, 2023 | Stephen K. Brannan | Chief Medical Officer | Sell | $427K (2,116 @ $201.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.